Christoph Nowak, MD, PhD

Developing the high-potency IL-1 inhibitor Isunakinra for the treatment of solid tumours in conjunction with a PD-1 checkpoint inhibitor, currently in Phase 2a in the US.

First-in-class inhaled therapy targeting small airway dysfunction in chronic obstructive pulmonary disease (COPD) approaching first-in-human testing in a Phase 1 trial.

Clinical-stage immunotherapy biotech with an innovative, oral, steroid-sparing drug candidate targeting VEXAS syndrome and other autoinflammatory diseases. Currently in fundraising mode.

Conducting a Phase 2 study in India to treat brain swelling with an intravenous treatment in acutely ill patients with traumatic brain injury (TBI) admitted to the ICU.

Medical expert in the registrational US-EU Phase 3 trial DIAGNODE-3.

Chief Medical Officer and Chief Business Officer of this pioneering public biotech company in autoimmune diabetes. Leadership of Diamyd´s registrational Phase 3 trial with its antigen-specific tolerizing recombinant protein therapeutic in Type 1 Diabetes and LADA. Leadership for successful fundraises in challenging public markets 2022-2024. Leadership for BD and important regulatory advances (importantly the FDA approval for C-peptide as a surrogate primary endpoint and submission for Accelerated Approval; and overcoming an FDA clinical hold).

Board Member of this entrepreneurial, public, clinical stage (registrational international Phase 3 trial) biopharmaceutical company developing a pioneering pain relief treatment for oral pain with the lead indication being oral mucositis in patients undergoing treatment for head and neck cancer. OncoZenge, which is supported amongst others by expert life sciences investor Linc AB, is a true turn-around story with a highly dedicated team of entrepreneurs.

My own consulting company; CMO/CBO, biostats, therapeutics business development, and venture capital due diligence. I am amongst others working (or have been working) on NewCo ideas and asset due diligence with Scandinavian life sciences investors and venture capital (VC) firms including Flerie, Hadean, and Innovestor.

Private entrepreneurial clinical stage biotech developing de-risked treatments for conditions with large unmet needs, with a focus on chronic cough. Successfully completed a Phase 2 trial in IPF patients with chronic cough in India.

Clinical-stage Paris-based biotech company of 40+ fantastic people pioneering a highly innovative technology targeting regulatory T cells (Tregs) for treatment of cancer and autoimmune diseases. For Egle's lead asset in autoimmunity, the Treg agonist EGL-003, I led the entry into the clinic in a first-in-human trial and the strategic/operational positioning for further clinical development in autoimmune diseases.

Assistant Professor in molecular epidemiology (Biträdande lektor i molekylär epidemiologi)

BM BCh (= MD) on 13 July 2013. Preclinical (years 1-3): Oriel College. Clinical (years 4-6): Balliol College Scatcherd European Scholarship (financed university & college fees, living expenses) With periods spent in Boise, Idaho (Family Medicine) and Marseille, France (Endocrinology)

"Insulin resistance: causes, biomarkers and consequences". Supervisors: Profs Tove Fall, Erik Ingelsson, Johan Sundröm. "Best thesis at Dept. of Medical Sciences" price.

Clinical Psychology